Browse the evidence

Tirzepatide, a dual GLP-1 and GIP receptor agonist, produces superior total body weight loss (up to 20.9% at 72 weeks) compared to placebo and other anti-obesity medications.

Tirzepatide is a highly effective weekly injection for obesity, achieving nearly 21% weight loss in clinical trials. It works by mimicking hormones that regulate hunger and digestion. While effective, it requires weekly injections and can cause gastrointestinal side effects like nausea.

Semaglutide, a GLP-1 receptor agonist, produces significant weight loss (up to 15.8% at 68 weeks) and improves cardiovascular outcomes in patients with obesity or type 2 diabetes.

Semaglutide is a highly effective weekly injection for obesity and type 2 diabetes, achieving nearly 15% weight loss in clinical trials. It works by mimicking the GLP-1 hormone, which regulates hunger and digestion. It also offers cardiovascular benefits, reducing the risk of heart attack and stroke.

GLP-1 receptor agonists (e.g., semaglutide 2.4 mg) produce clinically significant weight loss and reduce major adverse cardiovascular events (MACE) in adults with obesity or overweight, regardless of diabetes status.

GLP-1 medications like semaglutide are highly effective for weight loss and heart health, even if you don't have diabetes. While injections are common, oral versions exist. Be aware that cost and side effects (like nausea) can make sticking with the treatment difficult, so discuss these barriers with your doctor early.

Semaglutide (2.4 mg weekly) produces superior weight loss (14.9%) and significant cardiovascular risk reduction compared to placebo and other anti-obesity drugs.

If you have obesity and cardiovascular risks, semaglutide (2.4 mg weekly) is currently the most effective FDA-approved pharmacotherapy, offering significant weight loss and heart protection. Start with the lowest dose (0.25 mg) and titrate up to manage side effects. An oral version exists if you prefer avoiding injections.

Tirzepatide (up to 15 mg weekly) achieves the highest mean weight loss (up to 20.9%) among current pharmacotherapies but lacks FDA approval for cardiovascular risk reduction.

Tirzepatide (up to 15 mg weekly) offers the highest weight loss potential (up to 20.9%) among current drugs. However, it is not yet FDA-approved for cardiovascular risk reduction. Titrate the dose slowly to manage gastrointestinal side effects.

Dual GLP-1/GIP agonist tirzepatide (10-15 mg/week) produces superior weight loss (approx. 20.2%) compared to semaglutide (2.4 mg/week, approx. 13.7%) in patients with obesity.

If you are struggling with obesity and other treatments have failed, ask your doctor about tirzepatide. It is a weekly injection that targets hunger hormones and has been shown to produce greater weight loss than semaglutide. Be prepared for potential stomach issues, which usually improve over time, especially if the dose is increased slowly.

GLP-1 agonists (specifically semaglutide and liraglutide) reduce Major Adverse Cardiovascular Events (MACE) by 12-26% in patients with type 2 diabetes and obesity.

If you have type 2 diabetes and obesity, ask your doctor about the heart benefits of GLP-1 drugs. They can significantly reduce your risk of heart attacks and strokes, independent of weight loss.

Incretin therapies (GLP-1 and dual GLP-1/GIP receptor agonists) produce significant weight loss in adults with obesity by modulating incretin hormone pathways to suppress appetite and reduce caloric intake.

If you have obesity, incretin medications like semaglutide or tirzepatide are highly effective tools for weight loss, working by reducing appetite and slowing digestion. They are taken as weekly (or daily) injections and are most effective when combined with lifestyle changes like a reduced-calorie diet and regular exercise. Be aware that gastrointestinal side effects like nausea are common initially but often improve with slow dose increases. Long-term use is generally required to maintain weight loss, as stopping the medication often leads to weight regain.

Integrating incretin-based pharmacotherapy with structured patient education and behavioral therapy produces significantly greater and more durable weight loss than pharmacotherapy alone.

To get the best results from weight-loss medications, you should combine them with structured lifestyle changes and education. Studies show that patients who receive intensive behavioral support alongside medication lose significantly more weight and keep it off longer than those who rely on medication alone. Look for programs that offer coaching, dietary tracking, and regular check-ins.

Weekly subcutaneous semaglutide (2.4 mg) and tirzepatide (up to 15 mg) produce significantly greater mean weight loss (12-21%) in non-diabetic obese adults compared to daily liraglutide (3 mg, 5-8%) or placebo.

If you have obesity and are not diabetic, newer weekly injections like semaglutide (2.4 mg) or tirzepatide (up to 15 mg) are significantly more effective for weight loss than older daily options like liraglutide. Expect 15-20% body weight loss in clinical trials. Be prepared for gastrointestinal side effects, which usually improve over time. Crucially, stopping the medication typically leads to significant weight regain, suggesting long-term use may be necessary for sustained results.

GLP-1 receptor agonists (specifically semaglutide 2.4 mg and tirzepatide) produce significant weight loss (14.9-20.9%) and improve cardiometabolic risk factors in adults with overweight or obesity, regardless of diabetes status.

If you have overweight or obesity, GLP-1 agonists like semaglutide or tirzepatide are highly effective for weight loss, producing 15-21% body weight reduction in clinical trials. These benefits occur even if you do not have diabetes. Discuss these options with your provider, keeping in mind that cost and access may be barriers, but coverage is expanding for cardiovascular risk reduction.

Semaglutide (2.4 mg weekly) produces significant weight loss (approx. 15%) by acting as a GLP-1 receptor agonist that stimulates satiety centers in the hypothalamus.

Semaglutide is a weekly injectable medication that mimics a gut hormone to signal fullness to the brain. Clinical trials show it can lead to roughly 15% body weight loss when combined with lifestyle changes, significantly outperforming lifestyle changes alone. It requires a prescription and ongoing medical supervision.

Tirzepatide (5-15 mg weekly) produces dose-dependent weight loss (up to 25.3%) by acting as a dual GLP-1 and GIP receptor agonist.

Tirzepatide is a weekly injectable medication that mimics two gut hormones (GLP-1 and GIP) to regulate appetite and metabolism. Clinical trials show it can lead to up to 25% body weight loss, significantly outperforming placebo. It requires a prescription and ongoing medical supervision, and discontinuation leads to weight regain.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides superior glycemic control and substantial weight reduction compared to single-agonist therapies and placebo.

If you have Type 2 Diabetes or Obesity, Tirzepatide is a highly effective once-weekly injection that works by mimicking two gut hormones (GIP and GLP-1) to lower blood sugar and promote significant weight loss. It is generally considered superior to older single-agonist drugs. To use it safely, you must start with a low dose and gradually increase it to minimize stomach issues, while maintaining a healthy diet and exercise routine. Access may be limited by cost and insurance coverage, so discuss financial assistance or insurance prior authorization with your doctor.

Incretin-based therapies (GLP-1 and dual/triple agonists) produce clinically significant weight loss (15-21%) and improve cardiometabolic, renal, and hepatic outcomes, marking a turning point in obesity management.

Current GLP-1 and dual agonist medications are highly effective for significant weight loss and improving overall health markers like heart and liver function. They represent a major advancement over lifestyle changes alone, though they require long-term commitment and management of potential side effects like nausea.

Dual and triple incretin agonists (e.g., Tirzepatide, Retatrutide) achieve greater weight loss than single GLP-1 agonists by targeting multiple hormonal pathways.

Newer dual and triple hormone agonists offer even greater weight loss potential (up to 21%) than single-agonist GLP-1 drugs. They work by targeting multiple appetite and metabolism pathways simultaneously, making them highly effective for significant obesity.

Once-weekly subcutaneous semaglutide 2.4 mg induces significant weight loss (average 14.9% body weight) in non-diabetic adults with overweight or obesity compared to placebo.

If you have obesity and do not have diabetes, a once-weekly injection of semaglutide (2.4 mg) is a highly effective medical treatment that can lead to an average 15% reduction in body weight over 16 months. This is significantly more effective than placebo and addresses the biological drive to regain weight that often limits lifestyle changes alone.

Retatrutide and dual agonists achieved equivalent mean weight loss of -11.0 kg, surpassing GLP-1RAs which had a mean weight loss of -9.0 kg.

Practitioners can expect retatrutide and dual agonists to provide significant weight loss compared to GLP-1RAs.

Retatrutide excels at achieving ≥ 15% weight loss with an odds ratio of 54.6.

Retatrutide may be particularly effective for patients aiming for significant weight loss.

All obesity management medications (OMMs) showed significantly greater total body weight loss percentage (TBWL%) versus placebo.

Practitioners can consider OMMs as effective options for weight loss in adult patients.

Tirzepatide and semaglutide exceeded 10% total body weight loss and showed the most favorable glycaemic effects.

Tirzepatide and semaglutide may be prioritized for patients needing significant weight loss and glycaemic control.

Tirzepatide significantly reduced body weight compared to placebo, with a total pooled mean difference of -11.62 kg (95% confidence interval: -14.24 to -9.01, p < 0.001).

Tirzepatide can be considered an effective treatment option for weight loss in adults with obesity.

In the highest dosage group of 15 mg, 88.1%, 63.3%, and 51.8% of participants achieved weight reductions exceeding 5%, 10%, and 15% respectively.

Higher doses of Tirzepatide are associated with greater proportions of significant weight loss.

Cagrilintide-semaglutide resulted in a mean percent change in body weight of -20.4% from baseline to week 68 compared to -3.0% with placebo.

Cagrilintide-semaglutide may be an effective treatment option for significant weight loss in adults with overweight or obesity.